CC BY
10Targets. 2018;18(5):477-488. doi:
10.2174/1871530318666180531094508.
8. Javed A., Tebben P., Fischer P.R., Lteif A.N. Female athlete triad and its components: toward improved screening and management. Mayo Clin Proc. 2013 Sep;88(9):996-1009. doi: 10.1016/j.mayocp.2013.07.001.
9. Joy E., Kussman A., Nattiv A. 2016 update on eating disorders in athletes: A comprehensive narrative review with a focus on clinical assessment and management. Br J Sports Med. 2016 Feb;50(3):154-62. doi: 10.1136/bjsports-2015-095735.
10. L. Reshetnyk, M. Antonenko, N. Zelinskaya. Generalized parodontal diseases and anorexia nervosa: clinic-laboratory parallels. Science of Europe Vol 2 No 47 (2020), p. 53-58.
11. Malczyk Z., Oswi^cimska J.M. Gastrointestinal complications and refeeding guidelines in patients with anorexia nervosa. Psychiatr Pol. 2017 Apr 30;51(2):219-229. doi: 10.12740/PP/65274.
12. Mayhew A.J., Pigeyre M., Couturier J., Meyre D. An evolutionary genetic perspective of eating disorders. Neuroendocrinology. 2018;106(3):292-306. doi: 10.1159/000484525.
13. Mehler P.S., Brown C. Anorexia nervosa -medical complications. J Eat Disord. 2015 Mar 31;3:11. doi: 10.1186/s40337-015-0040-8.
14. Norris M.L., Harrison M.E., Isserlin L., Robinson A., Feder S., Sampson M. Gastrointestinal complications associated with anorexia nervosa: A systematic review. Int J Eat Disord. 2016 Mar;49(3):216-37. doi: 10.1002/eat.22462.
15. Nivedita N., Sreenivasa G., Malini S.S. Oxida-tive stress and abnormal lipid profile are common factors in students with eating distress. J Eat Disord. 2015 Nov 24;3:42. doi: 10.1186/s40337-015-0081-z.
16. Rosen E., Bakshi N., Watters A., Rosen H.R., Mehler P.S. Hepatic complications of anorexia nervosa. Dig Dis Sci. 2017 Nov;62(11):2977-2981. doi: 10.1007/s10620-017-4766-9.
17. Sachs K.V., Harnke B., Mehler P.S., Krantz M.J. Cardiovascular complications of anorexia nervosa: A systematic review. Int J Eat Disord. 2016 Mar;49(3):238-48. doi: 10.1002/eat.22481.
18. Spaulding-Barclay M.A., Stern J., Mehler P.S. Cardiac changes in anorexia nervosa. Cardiol Young. 2016 Apr;26(4):623-8. doi: 10.1017/S104795111500267X.
19. Stheneur C., Bergeron S., Lapeyraque A.L. Renal complications in anorexia nervosa. Eat Weight Disord. 2014 Dec;19(4):455-60. doi: 10.1007/s40519-014-0138-z.
20. Sudi K., Ottl K., Payerl D., Baumgartl P., Tauschmann K., Müller W. Anorexia athletica. Nutrition. 2004 Jul-Aug;20(7-8):657-61.
21. Solmi M., Veronese N., Manzato E., Sergi G., Favaro A., Santonastaso P., et al. Oxidative stress and antioxidant levels in patients with anorexia nervosa: A systematic review and exploratory meta-analysis. Int J Eat Disord. 2015 Nov;48(7):826-41. doi: 10.1002/eat.22443.
22. Sundgot-Borgen J., Torstveit M.K. Prevalence of eating disorders in elite athletes is higher than in the general population. Clin J Sport Med. 2004 Jan;14(1):25-32.
23. Tajiri K., Shimizu Y., Tsuneyama K., Sugiyama T. A case report of oxidative stress in a patient with anorexia nervosa. Int J Eat Disord. 2006 Nov;39(7):616-8.
ENDOTHELINE-1's DYNAMICS IN NON-PROLIFERATIVE DIABETIC RETINOPATHY AND ITS
CORRECTION WITH L-ARGININE
Semenko V.
graduate student of the Department of Ophthalmology SI "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine "
Abstract
Diabetic retinopathy (DR), as one of the most frequent and adverse manifestations of diabetes, remains the leading cause of significant visual impairment. Retina microstructural changes are detected at the DM onset, they gradually trigger the pathogenetic reactions cascade, which lead to microcirculation infringement and tissue hy-poxia. According to the classification of the American Diabetes Association, our study involved patients who were diagnosed with a non-proliferative stage of DR in the initial stage with the presence of single microaneurysms, spot hemorrhages or solid exudates. But for a more complete characteristic of step-by-step levels of change, to assess the progress of DR has been chosen criteria developed by a fundamental ETDRS study. The research involved 108 patients (216 eyes) diagnosed with type 2 diabetes between the ages of 45 and 60. Of these, 56 are men and 53 are women. Most patients (95 patients - 88%) experienced emetropic refraction. In 9 patients (8.3%) was determined myopic refraction, of which: 5 had mild myopia, and 4 had moderate myopia. 4 patients (3.7%) had low grade hypermetropic refraction. All patients' visual acuity is corrected. Thus, patients with different levels of ETDRS, depending on the level, also found unequal degree of endothelial dysfunction. The results obtained about the endothelial dysfunction characteristic for each endothelial dysfunction state can be considered as an informative characteristic of different levels of DR severity.
Performed metabolic correction with the use of L-arginine gave positive results. In patients after treatment were objectively determined stabilized DR state.
In patients who were prescribed metabolic correction with L-arginine was observed normalization of the vasoconstriction marker, there was a decrease in endothelin-1 level. The differences found are statistically significant at the significance level p <0.001. Prevention of vascular disorders further development, protection and maintenance of endothelial functions is one of the most important tasks of the DR treatment, in the early stages, during which the use of L-arginine is an effective remedy.
Keywords: diabetic retinopathy, endothelial dysfunction, L-arginine.
Introduction. Diabetic retinopathy (DR) is diagnosed in 50% of patients with type 1 diabetes (DM) with a disease duration of 10-15 years and in 75-90% of patients with a diabetes duration of more than 15 years [1]. Vascular pathology correction is one of the important DR treatment directions. The number of patients with DM increases annually and according to the State Register of the Ministry of Healthcare of Ukraine in Ukraine is already more than 1 million people, which is slightly less than 2% of the total population [2-4]. In this case, diabetic retinopathy has a special place among the complications of type 2 diabetes [5, 6]. DR, as one of the most frequent and adverse manifestations of diabetes, remains the leading cause of significant visual impairment [2, 7 - 10]. Retina microstructural changes are detected at the DM onset, they gradually trigger the pathogenetic reactions cascade [11-14], which lead to microcirculation infringement and tissue hypoxia.
Endothelial dysfunction is one of the key links in vascular dysfunction in diabetes [15]. There are a number of clinical and experimental studies in the literature that associated with endothelial disorders and arteries elastic properties to the diabetes vascular complications development [16-19]. Endothelial dysfunction (ED) leads to impaired nitric oxide (NO) synthesis, which plays an important physiological role, having a wide range of bioregulatory effects [20 - 22]. NO is characterized by vascular tone regulation, proliferation and apoptosis, oxidative processes regulation, angioprotective properties. All this is necessary for the vascular homeostasis regulation. It is also a strong peripheral vasodilator [21]. The main substrate for NO synthesis is arginine [22]. It performs number of important functions in the body, but its main role is that it's substrate for the nitric oxide synthesis [23-26]. Therefore, for the correction of ED, in particular for DM, this amino acid from which the endothelium can synthesize the necessary substances [27].
Materials and methods The research design and clinical characteristics of the patients were as follows. The criteria for inclusion in the research were the patient voluntary informed consent to participate in the research, age over 18 years, and for the research group - type 2 diabetes presence, verified DR. Patients examination and treatment with type 2 diabetes and DR were performed according to the WMA Declaration of
Helsinki, the Unified clinical protocol of primary and secondary (specialized) medical care. "Diabetes mellitus type 2" and the Order of the Ministry of Health of Ukraine dated 21.12.2012 No.1118 "On Approving and Implementation of Medical-Technological Documents on the Standardization of Medical Aids in Type 2 Diabetes"
According to the classification of the American Diabetes Association, our study involved patients who were diagnosed with a non-proliferative stage of DR [28] in the initial stage with the presence of single microaneurysms, spot hemorrhages or solid exudates. But for a more complete characteristic of step-by-step levels of change, to assess the progress of DR has been chosen criteria developed by a fundamental ETDRS study [29].
The research involved 108 patients (216 eyes) diagnosed with type 2 diabetes between the ages of 45 and 60. Of these, 56 are men and 53 are women. Most patients (95 patients - 88%) experienced emetropic refraction. In 9 patients (8.3%) was determined myopic refraction, of which: 5 had mild myopia, and 4 had moderate myopia. 4 patients (3.7%) had low grade hypermetropic refraction. All patients' visual acuity is corrected.
Research involved patients with a non-prolifera-tive stage of low-grade DR without evidence of clinically significant macular edema. Disease severity was determined by the ETDRS Final Retinopathy Severity Scale (for Individual Eyes) and corresponded to levels 14, 15, 20 and 35 (Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy ETDRS Report Number 12) [29].
Inclusion criteria: presence of single intraretinal microvascular abnormalities (IRMA), microaneurysms and/ or microhemorrhage, hard and soft exudate localized outside the macular area. These DR characteristics were determined in seven fields according to the modified Airlie House classification. According to the scheme of the specified classification, the fields localization is as follows (Fig. 1):
1 - is centered on the optic nerve disk (OND)
2 - is centered on the macula,
3 - is temporal to the macula,
4-7 - are fields tangential to the horizontal line passing between the upper and lower part of the OND and to the vertical line passing through the center of the macula [30].
Figure 1. Field localization according to the modified Airlie House classification.
Exclusion criteria were signs of subclinical macular edema or more pronounced stage of the macula [31], more advanced DR (presence of neoplasms, proliferation, etc.), retinal vessels thrombosis or embolism, age-related or other types of macular degeneration, pre-operative eye injury, surgical injury to the eye, including any kind of laser coagulation, vitreoretinal surgery, asteroid hyalosis.
Patients were divided into main and control groups. Main group' patients were prescribed 4.2% solution of L-arginine intravenously 100 ml 1 time a day for 10 days, followed by the transition to a solution for oral administration 5 ml 3 times a day for 4 weeks [32, 33].
Based on the blood pressure and glycosylated hemoglobin studies, groups were formed so that in each of the groups 50% of patients received arginine and 50% did not receive.
At the first stage, at the research beginning, all patients underwent pre-treatment with L-arginine: visometry, tonometry, biomicroscopy,
ophthalmoscopy.
Visometry was performed using Golovin-Sivtsev tables, Pole optotypes. Biomicroscopy was performed on a slit lamp PS - 615 by Topcon (Japan). A Goldman lens was used to inspect the peripheral mesh sections. Tonometry was performed with a Maklakov's applanation tonometer. For examination of the fundus was used direct and indirect binocular ophthalmoscope by Keeler (United Kingdom).
Endothelin-1 biochemical study in serum was performed by enzyme-linked immunosorbent assay (ELISA) using a set of Endothelin-1 DRG reagents (USA).
After 6 months from the research start, a was performed complete examination, including redetermination of the severity of DR by ETDRS in patients without L-arginine correction and on the background of its admission. At the same time were
determined biochemical parameters of the endothelium.
The following software was used for statistical data processing: IBM SPSS 19.0 (license number O6T4PC5YWM8GFB559ANSECAJEBF66JIHZUJZJ 2CHLXHUAQJD9YYEVITSVPXWIXPJHKTREQT CKF3HWWFPGBDCQZYEE77F4C4VPHM#, Matlab 7 (the serial number 1293-0415-9995-96099701).
Pairwise statistical averages comparisons for the series of quantitative data, each of which didn't differ from the normal distribution, were used with the Student's t-test with two-sided critical area for independent samples. Variable value shift analysis in the same patients at different stages was performed using the Student's criterion with two-sided critical area for the dependent samples.
Pearson's chi-squared (%2) test was used to compare the two empirical categorical data distributions. To compare qualitative dichotomous data was used the criterion "Fisher angular transformation" with Yates correction, the value of its statistics was denoted as T.
In all cases, statistical significance level was designated as "p". Significant were differences at p <0.05, high at p <0.01, very high at p <0.001.
Research results
Clinical trials results are presented in tables 1-3. Table 1 presents distribution of patients number who received and did not take L-arginine (2 subgroups of 54 patients) by ETDRS levels.
After 6 months, the patients status undergoing ETDRS remained unchanged. This is also confirmed by the absence of significant differences between distributions and in pairs between the patients number at the same level before and after treatment.
At the same time, the patients group who didn't take L-arginine changed the patients distribution by levels, showing the criterion "chi-square" with a high level of significance (p = 0.005).
Table 1
Distribution by DR severity (according to ETDRS) at the research beginning and depending on ___therapeutic tactics__
Patients groups Research stages Levels «14-20» Level «35» Level «43» Significant differences in distributions and frequencies (pair-wise)
Patients taking L-arginine First stage (before treatment) 12 42 0 -
After 6 months. 12 41 1
Patients who didn't take L-arginine First stage 12 42 0 X2=10,52; p=0,005 T43to-43after=3,38, p=0,001
After 6 months.. 7 38 9
Also in this group noteworthy level "43", in which the patients number increased statistically significant within 6 months from 0 (0.0%) to 9 (16.7%) patients. It is worth noting that the distributions themselves are also significantly different, indicating that patients are regrouped between the ETDRS levels, moreover, towards the worsening condition. This dynamics is illustrated in fig. 1.
45 40 35 m 30
m "l— X
CD
■=ï 25
CO _û
ö 20 _û
s 15 10 5 0
1 eian 3 apriHiHOM I I 2 eian 3 apriHiHOM KgJ 1 eian 6e3 apriHiHy
2 eian 6e3 apriHiHy
piBeHb 14-20 piBeHb 35 piBeHb 43
Fig. 1. Distribution by DR severity (according to ETDRS) at the research beginning and depending on
therapeutic tactics
Endothelin-1 determination was made at the research beginning (Table 2, Fig. 2) and after 6 months (Table 3, Fig. 3). Comparison of endothelial indicators functional status in patients with different levels of DR severity.
Table 2
Endothelin-1 level research results in the first stage of the study. Comparison between levels of DR __severity (according to ETDRS) ^_
Levels «14-20» 24 patients Level «35» 84 patients Statistical significance of differences
endothelin-1 0,268±0,010 0,382±0,007 <0,001
eNO- synthase 0,728±0,013 0,584±0,006 <0,001
It's detected that with the progression of DR is the pathological vasoconstriction development, which can be judged by a significant increase in endothelin-1 in patients with 35 levels of diabetic retinopathy (according to the classification of ETDRS).
0,40 0,38 0,36 0,34
_o
§ 0,32 0,30 0,28 0,26 0,24
Fig. 2. Analysis results of endothelin-1 content in the blood of patients at the first research stage. Comparison
between levels of DR severity (respectively ETDRS).
Table 3
Analysis results of endothelin-1 content in the blood of patients at the first research stage. Comparison __between levels of DR severity (respectively ETDRS).. Second stage _
1 2 3 4 5 6
Stage 2 without L-arginine -levels 14-20 7 patients Stage 2 with L-arginine - levels 14-20 12 patients Stage 2 without L-arginine -level "35" 38 patients Stage 2 with L-arginine -level "35" 41 patient Stage 2 without L-arginine -level "43" 9 patients Stage 2 with L-arginine -Level 43 1 patient
Endothelin-1 0,466±0,020 0,211±0,021 P12*** 0,679±0,006 0,314±0,008 P12*** 0,762±0,009 0,70
Footnote:
■ p<0,001
In Fig. 3 vasoconstrictor
0,8
0,7 0,6 „ 0,5
0,4
0,3
0,2
0,1
shows the tendency to normalize potential in patients receiving L-
arginine, a positive therapeutic effect was found in patients in all study groups.
2 eTan 6e3 apriHiHy 2 eTan 3 apriHiroM
piBeHb 14-20
piBeHb 35
piBeHb 43
Fig. 3. Analysis results of endothelin-1 content in the blood ofpatients at the second research stage. Comparison
between levels of DR severity (respectively ETDRS).
Thus, patients with different levels of ETDRS, depending on the level, also found unequal degree of endothelial dysfunction. The results obtained about the endothelial dysfunction characteristic for each endothelial dysfunction state can be considered as an informative characteristic of different levels of DR severity.
Performed metabolic correction with the use of L-arginine gave positive results. In patients after treatment were objectively determined stabilized DR state.
In patients who were prescribed metabolic correction with L-arginine was observed normalization of the vasoconstriction marker, there was a decrease in endothelin-1 level. The differences found are
statistically significant at the significance level p <0.001.
Prevention of vascular disorders further development, protection and maintenance of endothelial functions is one of the most important tasks of the DR treatment, in the early stages, during which the use of L-arginine is an effective remedy.
Conclusion:
1. The use of L-arginine allowed to stabilize the clinical course of diabetic retinopathy. After 6 months, the patients status treated with arginine as a part of complex therapy remained unchanged.
2. In the patients group who didn't use L-arginine draws attention to the level of "43", in which the number of patients increased significantly within 6 months. Patients were regrouped between the ETDRS levels in the direction of worsening.
3. It were determined differences between endo-thelin-1 indices depending on the severity of ETDRS severity (14, 15, 20 and 35 levels).
4. As a result of L-arginine therapy was observed normalization of the vasoconstriction marker in the patients who participated in the research.
5. It is proved that arginine is the main substrate for NO synthesis. Consequently, for the endothelial dysfunction correction, in particular in diabetic reti-nopathy, this amino acid is needed. This is acid from which the endothelium will be able to synthesize the necessary substances.
References
1. Zelins'ka N.B., Horoshaja O.O., Starinec' N.A. Chastota diabetichnoi' retinopatii u hvorih na CD ditej ta pidlitkiv za danimi skriningu v regionah Ukraini. Klinichna endokrinologija ta endokrinna hirurgija. 2005;4:27-31.
2. Saharosnizhajushhaja terapija u pacientov s saharnym diabetom 2 tipa i serdechno-sosudistoj patologiej / A.S. Efimov, L.K. Sokolova // Endokrinologija. - 2012. - T. 17, № 4. - S. 23-26
3. Sidorova M.V. Diabetichna retinopatija patogenez, klinika, likuvannja. Kiiv, 2006:93-98.
4. Smirnova O.M. Diabeticheskaja retinopatija. Rezul'taty mezhdunarodnyh mnogocentrovyh issledovanij. Saharnyj diabet. 2010;1:82-87
5. IDF Diabetes Atlas. 6-th edition. 2013. Available from: http://www.idf.org/diabetesatlas
6. Vijan S., Hofer T.P., Hayward R.A. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7):889-896.
7. Alifanova T.A., Kushnir N.N. Diabet i problema invalidnosti. II Mizhnarodna konferencija oftal'mologiv Prichornomorja. Odesa, 2004:124.
8. Wild S., Roglic G., Green A. Global prevalence of diabetes: estimates for the year 2000 and proejection for 2030. Diabetes Care. 2004;27:1047-1053.
9. Kryzhanovskaja T.V. Patogeneticheskie aspekty reabilitacii bol'nyh diabeticheskoj retinopatiej. Mater. 2-oj Mezhd. Konf. «Sovremennye aspekty sosudisto-jendokrinnyh zabolevanij organa zrenija». K., 2005:73- 74.
10. Pasechnikova N.V., Naumenko V.A., Zborovskaja A.V. Klinicheskaja klassifikacija i taktika lazernogo lechenija bol'nyh s diabeticheskim makuljarnym otekom. Odes'kij medichnij zhurnal. 2009;116(6):77-79.
11. Hammes H.P., Lin J., Renner O., Shani M., Lundqvist A., Betsholtz C., Brownlee M., Deutsch U. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002 Oct;51(10):3107-12.
12. Stitt A.W. Advanced glycation: an important pathological event in diabetic and age related ocular disease. British Journal of Ophthalmology 2001;85:746-753.
13. Shestakova M.V., Chugunova L.A., Sham-halova M.Sh, Dedov II. Diabeticheskaja nefropatija: dostizhenija v diagnostike, profilaktike i lechenii. Saharnyj diabet. 2005;3:22-25.
14. Dagher Z., Park Y.S., Asnaghi V., Hoehn T., Gerhardinger C., Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes. 2004 Sep;53(9):2404-11.
15. Kosobjan E.P., Jarek-Martynova I.Ja., Par-fjonov A.S., Shestakova M.V. Vazomotornaja funkcija jendotelija i jelastichnost' arterial'noj stenki u pacientov s saharnym diabetom 1-go tipa na raznyh stadijah dia-beticheskoj retinopatii. Problemy jendokrinologii. 2012;4:22-26.
16. Balabolkin M.I. Rol' glikirovanija belkov, okislitel'nogo stressa v patogeneze sosudistyh oslozhnenij pri saharnom diabete. Saharnyj diabet. 2002;4:8-16.
17. Verma S., Buchanan M.R., Anderson T.J. En-dothelial Function Testing asa Biomarker of Vascular Disease. Circulation. 2003;108:2054-2059.
18. Bonetti P.O., Lerman L.O., Lerman A. Endothelial Dysfunction: A Markerof Atherosclerotic Risk. Arterioscler Thromb Vascular Bio. 2003;23:168-175.
19. Widlansky M.E., Gokce N., J.F. Jr. Keaney, Vita J.A. The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology. 2003;42:1149-1160.
20. Chatterjee A., Catravas J.D. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vas-cul. Pharmacol. 2008;49(4-6):134-140.
21. Gudyrev O.S., Radzhkumar D.S.R., Fajtel'son A.V. i dr. Osteoprotektivnoe dejstvie L-arginina pri jeksperimental'nom osteoporoze. Nauchnye vedomosti BelGU. Ser. Medicina. Farmacija. 2012;20/3;22(141):94-97.
22. Reutov V.P., Sorokina E.G., Ohotin V.E., Kosicyn N.S. Ciklicheskie prevrashhenija oksida azota v organizme mlekopitajushhih. M.: Nauka. 1997.
23. Bryan N.S., Bian K., Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Frontiers in Bioscience. 2009;14:1-18.
24. Babushkina A.V. L-arginin s tochki zrenija dokazatel'noj mediciny. Ukr. Med. Chasopis. 2009;74(XI/XII):43-48
25. Boger R.H., Nutr J. The pharmacodynamics of L-arginine. 2007;137:1650-1655.
26. Lisicyna N.V. Medikamentoznye sredstva, vlijajushhie na sintez oksida azota i ih mesto v patoge-neticheskoj terapii prejeklampsii. Nauchnye vedomosti BelGU. Ser. Medicina. Farmacija. 2010;10(81):46-54.
27. Lishnevskaja V.Ju. Jendotelial'naja dis-funkcija: chto neobhodimo znat' prakticheskomu vra-chu? Zdorov'ja Ukraïni. 2010;7:2.
28. American Diabetes Association. (2008) Diabetes Care. Suppl 1.
29. Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy ETDRS Report Number 12. Ophthalmology. 1991;98:823-833.
30. Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs - An Extension of the Modified Airlie House Classification. ETDRS Report Number 10. Ophthalmology. 1991;98:786-806.
31. Pasechnikova N.V., Naumenko V.A., Zborovskaja A.V. Klinicheskaja klassifikacija i taktika lazernogo lechenija bol'nyh s diabeticheskim ma-kuljarnym otekom. Odes'kij medichnij zhurnal. 2009;116(6):77-79.
32. Konopleva L.F., Andreev E.V. L-Arginin pri ishemicheskoj bolezni serdca: issledovanija prodolzhajutsja. Theraria. 2010;10(51):64-68.
33. Monti L.D., Setola E., Lucotti P.C., Marrocco-Trischitta M.M., Comola M., Galluccio E., Poggi A., Mammi S., Catapano A.L., Comi G., Chiesa R., Bosi E., Piatti P.M. Effect of a long-termoral l-arginine supplementation on glucosemetabolism: a randomized, double-blind, placebo-controlled trial. Diabetes, obesity and metabolism. 2012;14:893-900.
INFLUENCE OF SEX HORMONES LEVEL ON DEVELOPMENT AND CLINICAL MANIFESTATIONS OF ROSACEA, DEMODICOSIS AND PERIODIC DERMATITIS
Chornenka Zh.
Abstract
Introduction. Among the links of the pathogenesis of demodicosis include an increase in production and a change in the composition of sebum, which is explained by the characteristics of the metabolism and function of the sebaceous glands controlled by androgens. Such changes during puberty are due to an increase in the sensitivity of the androgen receptors of the sebaceous glands to male sex hormones, often with a normal physiological composition and level of blood androgens. However, in some patients, demodicosis occurs and persists against the background of pathological conditions caused by central hyperandrogenemia. Numerous researchers emphasize that the persistent course of demodicosis can support background diseases, the persistence of demodecosis after the end of the puberty is possible under the influence of additional trigger factors, which are important to identify during the examination. At the same time, in literary sources, algorithms for examining adolescents with demod-icosis are not adequately covered.
Keywords: demodicosis, rosacea, sex hormones, clinical manifestations.
The skin takes an active part in the metabolism of steroid hormones, and many skin functions (synthesis of intercellular lipids, hair growth, mitotic activity of the epidermis) are influenced by androgens. Under the influence of the enzyme 5-reductase from testosterone, its more active metabolite, dehydrotestosterone, arises. An increase in androgenic and enzymatic activity in puberty leads to the fact that more and more previously inactive sebaceous glands begin to produce sebum. The secretion of fat depends on many factors: ambient temperature, patient age, phase of the menstrual cycle, biological rhythm.
However, to date, there are no reports in the literature on the study of levels of sex hormones in the body of men suffering from rosacea, demodicosis and dermatitis perioral, in particular, depending on the severity of the clinical course of these dermatoses, as well as taking into account the presence of ticks-demicides.
The work presents the data of examination of 479 patients with inflammatory processes of the face skin, among which 227 were diagnosed with rosacea, in 196
- demodicosis, in 56 - perioral dermatitis. The age of the examined patients ranged from 28 to 76 years old, according to the sex of women it was 293 (61%), men
- 186 (39%).
Laboratory diagnostics for detection of D. follicu-lorum and D. brevis ticks was carried out by microscopic examination of pathological material taken from
patients with inflammatory process foci on the face skin and eyelids of eyes. The material for the study was scales, pus pustules, and the contents of the sebaceous gland outlet ducts.
The level of individual sex and gonadotropic hormones in the serum of male patients was studied using immunoassay test systems (DRG International. Inc., USA). An approximate estimation of hormonal (androgenic) saturation of patients was carried out by andro-genic intracellular sample and crystallographic method of biological substrates research.
Among the 227 patients tested for rosacea were 133 (59%) women and 94 (41%) men. The age of patients ranged from 34 to 76 years. Depending on the age, patients with rosacea were as follows: 34-39 years - 13 (6%), 40-49 years - 24 (11%), 50-59 years - 95 (41%), 60-69 years - 83 ( 37%), older than 70 years -12 (5%).
The average age of the surveyed women with rosacea was 47.8 years and men - 53.7 years. The distribution of patients depending on the duration of dermatosis was as follows: up to 1 year - 23 (10%), from 1 to 5 years - 66 (29%), from 5 to 10 years - 63 (28%), over 10 years - 75 (33%).
In determining the extended clinical diagnosis in our patients with rosacea, we followed the classification of this dermatosis used in Europe and the United States.
